New: AI Privacy Impact Assessments for teams shipping AI features. Learn about AI-PIAs
Digital health & life sciences
Privacy & Security for Biotech & Pharma Companies
A biotech or pharma company's privacy and security program has to answer for three separate categories of sensitive data at once: key-coded trial records, patient support program enrolments, and the scientific IP behind the pipeline. Each is governed by a different rulebook, and each is often held by a different vendor. The trigger is rarely a single deadline — it is a licensing partner's diligence team, a hub-vendor incident, or a Health Canada inspection of computerised systems. We build the programs that keep GCP/GMP inspectors, partnering counsel and Canadian privacy regulators satisfied with the same evidence.
Reviewed by the Privacy Horizon team · Last reviewed
Who this is for
Discovery-stage biotechs, often 15 to 40 people, holding unfiled scientific IP worth more than the company itself and no in-house security function, competing for licensing deals where the counterparty's diligence team audits data protection before signing.
Clinical-stage companies carrying sponsor-side obligations under Division 5 of the Food and Drug Regulations, coordinating CROs, trial sites and REBs while a 15-year record-retention clock keeps running long after any given system is retired.
Generic and specialty manufacturers, plus multinational affiliates, operating patient support programs through third-party hub and specialty-pharmacy vendors, where the identifiable layer of their own drug's patients usually sits outside the sponsor's own walls.
VP Regulatory/Quality, General Counsel, Heads of IT, VP Clinical Operations and Patient Services leads who need one coherent program rather than three disconnected ones — satisfying GCP/GMP inspectors, partnering counsel and Canadian privacy regulators without duplicating the underlying work.
Services
Privacy & security services for biotech & pharma companies
Each service below is scoped for how biotech & pharma companies actually operate — their systems, their regulators and the reviews they face.
Virtual CISO
Virtual CISO for Biotech & Pharma Companies
vCISO for Canadian biotech and pharma companies: IP-focused security leadership, licensing-diligence readiness, and lab/GxP network segmentation.
Virtual Privacy Officer
Virtual Privacy Officer for Biotech & Pharma Companies
Virtual Privacy Officer for Canadian biotech and pharma: trial-data classification, PSP hub accountability, and Quebec Law 25 readiness, from $2,200/month.
Penetration Testing
Penetration Testing for Biotech & Pharma Companies
Penetration testing for Canadian biotech and pharma companies: external portals, ELN/LIMS apps and GxP-validated systems tested without breaking validation.
Incident Response Planning
Incident Response Planning for Biotech & Pharma Companies
Incident response planning for Canadian biotech and pharma: hub vendor breach protocols, ADR reporting continuity, and OPC notification decisions.
Privacy & Security Policy Development
Privacy & Security Policy Development for Biotech & Pharma Companies
Privacy and security policy development for Canadian biotech and pharma: data-integrity policies GCP/GMP inspectors accept, plus PSP consent language.
Privacy & Security Training
Privacy & Security Training for Biotech & Pharma Companies
Privacy and security training for Canadian biotech and pharma teams: role-specific modules for patient-services staff, bench scientists and pharmacovigilance.
Vendor Security Review & Questionnaire Support
Vendor Security Review & Questionnaire Support for Biotech & Pharma Companies
Vendor security review for Canadian biotech and pharma companies qualifying CROs, PSP hubs, labs and cloud vendors holding trial and patient data.
ISO 27001 Readiness
ISO 27001 Readiness for Biotech & Pharma Companies
ISO 27001 readiness for Canadian biotech and pharma companies: a scoped ISMS covering R&D and PSP operations to shorten repeated partner diligence reviews.
HIPAA Readiness
HIPAA Readiness for Biotech & Pharma Companies
HIPAA readiness for Canadian biotech and pharma: classifying US patient data as authorization-based, a limited data set, or business associate territory.
M&A Privacy & Security Due Diligence
M&A Privacy & Security Due Diligence for Biotech & Pharma Companies
Privacy and security due diligence for Canadian biotech and pharma deals: trial data, PSP hub contracts, pharmacovigilance history and IP protection reviewed.
What you hold
What a biotech or pharma privacy and security program has to cover
The data at risk splits three ways in this sector, and each category carries its own owner, its own retention clock and its own worst-case failure mode.
Key-coded trial datasets and safety narratives
EDC, eTMF and safety-database records tied to a re-identification key that the sponsor may or may not directly hold, feeding case narratives that must stay complete and verifiable for years, not months.
Patient support program enrolment records
Diagnosis, prescribed drug, insurer and consent details captured at enrolment and frequently processed entirely inside a third-party hub or specialty-pharmacy platform rather than the sponsor's own systems.
Unfiled scientific IP
Sequences, synthesis routes and dossiers whose entire commercial value depends on staying undisclosed until a patent filing or a licensing deal closes — a loss no breach-notification duty can reverse.
Adverse-event and pharmacovigilance case files
Patient-level health information moving through safety databases under short statutory reporting windows, drafted and forwarded under time pressure during a reporting crunch.
Lab, manufacturing and cold-chain systems
LIMS, ELN, GMP batch records and cold-chain telemetry running on instrument networks that were rarely designed with any separation from the corporate domain.
HCP engagement and marketing platforms
Prescriber-interaction records and program mailing lists held in CRM and marketing-cloud tools, a common secondary target once the primary trial and PSP systems are locked down.
Regulatory map
The regulatory map a biotech or pharma buyer already expects you to know
Sponsors, inspectors and partnering counsel in this sector treat Division 5 and Canadian privacy law as one combined expectation, not two separate checklists to satisfy in turn.
Division 5 good clinical practice and REB approval
Sponsors of clinical trials must conduct them according to good clinical practices and hold Research Ethics Board approval for every participating site before enrolment begins.
A 15-year trial record-retention clock
Sponsors must record and store trial information so it allows complete and accurate reporting, interpretation and verification, and keep those records for fifteen years — well past most system lifespans.
Serious unexpected adverse-drug-reaction windows
Trial sponsors must report serious unexpected adverse drug reactions within fifteen days, or seven days if the reaction was fatal or life-threatening, regardless of what else is happening in the organization.
Marketed-product pharmacovigilance reporting
Once a product is on the market, manufacturers must still report serious adverse drug reactions to Health Canada within fifteen days, keeping patient-level case data moving through safety systems indefinitely.
PIPEDA obligations for PSPs and HCP data
Patient support programs, HCP marketing lists and employee records fall under PIPEDA in most provinces, including mandatory breach reporting to the federal regulator on a real-risk-of-significant-harm standard.
US exposure without covered-entity status
Pharma companies generally are not HIPAA covered entities; US patient data usually arrives under a patient's own authorization or as a limited data set rather than through a business associate arrangement.
What goes wrong
The incident patterns specific to trial, PSP and IP data
The failure modes that recur in this sector rarely start inside the sponsor's own four walls — they start at a vendor, a lab, or a system nobody in security was watching.
Hub or PSP vendor compromise
A breach at the third-party hub running a patient support program can expose enrolees' names, diagnoses and medications long before the sponsor whose drug is named even learns of the incident.
Ransomware in trial-critical SaaS
An attack on a shared eClinical or EDC provider can force sites back onto pen and paper mid-study, delaying data capture and putting reporting timelines and data integrity both at risk.
IP theft targeting research and manufacturing know-how
Sophisticated actors go after sequences, synthesis routes and process documentation rather than patient records, because unfiled science can be worth more than anything a privacy law protects.
Credential stuffing against genomic and consumer-health platforms
Accounts protecting genetic or health-profile data without multi-factor authentication have been the entry point in large-scale credential-stuffing campaigns examined by Canadian and international privacy regulators.
Case-narrative mishandling during reporting crunches
Identifiable adverse-event files circulating by email while a fifteen-day or seven-day clock is running is a recurring failure mode wherever pharmacovigilance staff lack a secure, fast-enough alternative.
Third-party leaks of HCP and program mailing lists
Marketing and CRM vendors holding prescriber and patient-program lists create a breach surface that sits outside the sponsor's own security controls but still triggers the sponsor's own notification duties.
When organisations call us
When biotech and pharma companies call Privacy Horizon
The calendar for this niche runs on deal timelines and inspection schedules more than on any single recurring compliance date.
A licensing or financing deal opens diligence
A partnering counterparty or investor's diligence team starts auditing data protection and data integrity before terms close, and the evidence has to already exist rather than be assembled overnight.
A hub-services incident surfaces
News breaks of a breach at a PSP hub or specialty pharmacy handling the company's own patients, and Patient Services, Legal and IT need an answer within hours, not weeks.
An upstream trial system goes down
A ransomware event or outage at an EDC, eTMF or IRT vendor threatens study timelines, and the sponsor needs a documented response that keeps regulatory clocks defensible.
A GxP inspection raises a data-integrity finding
A Health Canada inspection of computerised systems flags a gap in access control, audit trail or record retention that now needs a remediation plan a CISO can actually execute.
Cyber-insurance underwriting asks about IP exposure
A renewal or new policy application asks pointed questions about how unfiled research is segmented and protected, questions the company has never had to answer in writing before.
Quebec's Law 25 reaches a patient program
A PSP or consumer program serving Quebec residents needs its privacy impact and incident-notification obligations reviewed against Law 25 on top of the federal baseline.
Biotech & Pharma Companies: privacy & security questions, answered
Most healthcare organizations manage one dominant category of sensitive data. A biotech or pharma company manages three at once — key-coded trial data, PSP enrolments, and unfiled scientific IP — each with a different owner and a different regulator watching it. A program built for hospitals or SaaS vendors will miss at least one of the three.
Yes, and earlier than most founders expect. A fifteen-person discovery biotech with unfiled IP and no security staff is exactly the profile a licensing partner's diligence team scrutinizes hardest, precisely because there is no internal function to answer their questions. Leadership can be brought in without a full-time hire.
Expect questions on how research and clinical data are segmented from corporate systems, who can access unfiled science, how trial data integrity is maintained, and what happened the last time something went wrong. Diligence teams are pricing risk, not filling out a checklist, so vague answers cost more than gaps that are already being fixed.
Trial records under Division 5 of the Food and Drug Regulations carry a fifteen-year retention requirement, which typically outlasts the EDC, eTMF or IRT system that originally captured the data. Planning for that mismatch — migration, archival format, continued access — belongs in the program from day one, not as an afterthought when a system is decommissioned.
Inspectors look at whether computerised systems supporting trials or manufacturing maintain accurate, attributable, verifiable records — access control, audit trails and system validation all bear on that finding. A security program built without reference to those inspection expectations can pass a generic audit and still draw a data-integrity observation.
One combined program works better than two parallel ones, because the same trial and PSP data often flows through both jurisdictions. We build a single framework that documents where PIPEDA, provincial privacy law and US authorization or limited-data-set rules each apply, rather than maintaining separate binders that drift apart over time.
Related industries
Answers & guides
- What is privacy and security due diligence in an acquisition?
- What is a vCISO, and when do you need one?
- Does HIPAA apply to my software or business?
- What is PIPEDA, and does it apply to my business?
- What should I do after a data breach?
- VPO vs vCISO: do you need one, the other, or both?
- Privacy and Cyber Due Diligence Before You Acquire a Company
- The Privacy and Security Problems That Quietly Erode Deal Value
- The First 24 Hours After a Privacy Breach: A Canadian Response Playbook
- PIPEDA Breach Notification and Record-Keeping: What to Get Right
- The Canadian Privacy Law Landscape in 2026: PIPEDA, PHIPA, and Quebec Law 25
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.